Storia in 5 fonti

Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades

Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.

Raccontata da

lunedì 23 febbraio 2026·cnbc.com
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
lunedì 23 febbraio 2026·ansa.it
Novo Nordisk scivola in Borsa (-8%) dopo dati deludenti per Cagrisema - Notizie - Ansa.it
Seduta pesante per la multinazionale danese del farmaco Novo Nordisk dopo aver reso pubblici dati deludenti sulla sperimentazione della terapia antiobesità Cagrisema. (ANSA)

lunedì 23 febbraio 2026·

cincodias.elpais.com

Novo Nordisk vuelve a hundirse en Bolsa al fallar los ensayos de su nuevo medicamento contra la obesidad

La acción cae hasta un 16% y se deja ya un 75% desde mediados de 2024. El grupo danés se queda por detrás de su rival estadounidense Eli Lilly

lunedì 23 febbraio 2026·

theguardian.com

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations

lunedì 23 febbraio 2026·

ft.com

Novo Nordisk shares drop 15% after poor trial results for new obesity drug

Once-a-week injection achieved less weight loss than rival treatment

lunedì 23 febbraio 2026·

cnbc.com

Eli Lilly's lead in the obesity race gets wider after another win against rival Novo Nordisk

Lilly shares rose more than 4% Monday, while rival Novo Nordisk tanked.

martedì 24 febbraio 2026·

cnbc.com